Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F25%3A00637878" target="_blank" >RIV/60077344:_____/25:00637878 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/25:00141847 RIV/00027162:_____/25:N0000088
Result on the web
<a href="https://doi.org/10.1016/j.bcp.2025.117125" target="_blank" >https://doi.org/10.1016/j.bcp.2025.117125</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bcp.2025.117125" target="_blank" >10.1016/j.bcp.2025.117125</a>

Result language
angličtina
Original language name
Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention
Original language description
Lenacapavir (GS-6207) is a capsid inhibitor approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced people with multidrug-resistant HIV-1. Here, this study provides a comprehensive overview of lenacapavir, with a particular focus on its long-acting properties, pharmacodynamics, pharmacokinetics, clinical efficacy and safety, and resistance profile. Clinical trials have demonstrated that long-acting lenacapavir is highly effective not only for treating HIV-1 infection but also as a pre-exposure prophylactic agent. The future development of fixed-dose, long-acting combination regimens incorporating lenacapavir and other long-acting antiretroviral agents offers significant potential for durable and effective HIV-1 management in clinical settings.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)